Transdermal administration of tamsulosin

• US 9,610,253 B2
• Filed: 07/03/2014
• Issued: 04/04/2017
• Est. Priority Date: 01/14/2009
• Status: Active Grant

• Current Assignee: Corium Pharma Solutions, Inc.
• Original Assignee: Corium International, Inc.
• Inventors: Singh, Parminder, Lee, Eun Soo, Jain, Amit K.
• Primary Examiner(s): Haghighatian, Mina
• Application Number:
  US14/323,958
• Publication Number:
  US 20140322284A1
• Time in Patent Office: 1,006 Days
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/18 Sulfonamides compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/12 Carboxylic acids; Salts or anhydrides thereof
• CPC Class Codes: A61K 47/14 Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/70 Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug hollow drug-filled fibres A61K9/0092
• CPC Class Codes: A61K 9/7023 Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006
• CPC Class Codes: A61K 9/7053 obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
• CPC Class Codes: A61P 13/08 of the prostate

Abstract

In an aspect of the invention, a composition for making a patch for the transdermal delivery of tamsulosin is provided. The composition comprises (a) at least about 1 wt % tamsulosin or a pharmaceutically acceptable salt of tamsulosin, (b) at least about 40 wt % polyisobutylene adhesive or hydrophobic synthetic rubber adhesive, (c) about 1-20 wt % of an aprotic solvent in which tamsulosin dissolves readily, (d) about 1-20 wt % of an unsaturated fatty acid or an alpha-hydroxy acid or a mixture of unsaturated fatty acids or alpha-hydroxy acids or of both unsaturated fatty acids and alpha-hydroxy acids, (e) a lipophilic permeation enhancer, and (f) a matrix modifier.

Claims

1. A composition for delivery of tamsulosin, comprising an adhesive matrix comprised of:

polyisobutylene;

a solvent selected from dimethylacetamide, n-methylpyrrolidone and dimethylsulfoxide;

a mixture of an unsaturated fatty acid and an alpha-hydroxy acid;

a permeation enhancer of the formula CH₃(CH₂)_mOCOCHR1R2,

where m is an integer in the range of 6 to 14,

R1 and R2 are each independently selected from hydrogen, hydroxyl, and a C1-C2 lower alkyl group, wherein at least one of R1 and R2 is hydroxyl or both R1 and R2 are hydrogen, and

tamsulosin.

2. The composition of claim 1, wherein the solvent is dimethylsulfoxide.

3. The composition of claim 2, wherein the adhesive matrix comprises dimethylsulfoxide and tamsulosin in a weight ratio of at least 1.2.

4. The composition of claim 1, wherein the adhesive matrix comprises a molar ratio of alpha-hydroxy acid to tamsulosin of at least 0.1.

5. The composition of claim 1, wherein the unsaturated fatty acid is selected from the group consisting of oleic acid, linoleic acid, and linolenic acid.

6. The composition of claim 1, wherein the unsaturated fatty acid is a fatty acid with 11 to 21 carbon atoms.

7. The composition of claim 1, comprising at least about 40 wt % polyisobutylene.

8. The composition of claim 1, wherein the permeation enhancer is present at about 1-20 wt %.

9. The composition of claim 1, wherein the permeation enhancer is either methyl laurate or lauryl lactate.

10. The composition of claim 1, wherein tamsulosin is tamsulosin base.

11. The composition of claim 1, wherein the adhesive matrix further comprises colloidal silicone dioxide or fumed silica.

12. The composition of claim 1, wherein tamsulosin is a salt of tamsulosin and the matrix further comprises a neutralizing agent.

13. A method for administering tamsulosin, comprising:

providing to a subject a composition according to claim 1.

14. A method for treating benign prostatic hyperplasia, comprising:

providing to a subject a composition according to claim 1.

15. The composition of claim 1, wherein the alpha-hydroxy acid is selected from the group consisting of lactic acid and glycolic acid.